Takeshi Namekawa1, Satoshi Fukasawa1, Atsushi Komaru1, Masayuki Kobayashi1, Yusuke Imamura1, Takayuki Ohzeki1, Kimiaki Takagi1, Yosuke Sato1, Koichiro Akakura2, Tomohiko Ichikawa3, Takeshi Ueda4. 1. Prostate Center and Division of Urology, Chiba Cancer Center, 666-2 Nitona-cho, Chuo-ku, Chiba, Chiba, 260-8717, Japan. 2. Division of Urology, Japan Community Health Care Organization, Tokyo Shinjuku Medical Center, Tokyo, Japan. 3. Department of Urology, Graduate School of Medicine, Chiba University, 1-8-1 Inohana-cho, Chuo-ku, Chiba, 260-8670, Japan. 4. Prostate Center and Division of Urology, Chiba Cancer Center, 666-2 Nitona-cho, Chuo-ku, Chiba, Chiba, 260-8717, Japan. urolccc@yahoo.co.jp.
Abstract
BACKGROUND: Although transperineal (TP) prostate biopsy is growing in popularity, its safety has not been evaluated based on extensive studies. We prospectively assessed the adverse events associated with transrectal ultrasound (TRUS)-guided TP 16-core prostate biopsy at a single institution. PATIENTS AND METHODS: We enrolled 2,086 males who underwent first-time TRUS-guided TP prostate biopsy under lumbar spinal anesthesia at Chiba Cancer Center between 2009 and 2013. Eight adverse events were assessed prospectively using a purpose-designed questionnaire. The prevalence and duration of all adverse events were evaluated. We performed subgroup analyses for hematuria and urinary retention in relation to clinical factors. RESULTS: Questionnaires were collected from 1,663 cases (79.7 %). The cancer detection rate was 53.5 % in all patients. The prevalence and duration of complications were as follows: hematuria, 73.4 % and 4.51 ± 2.88 days; perineal bleeding, 7.1 % and 2.20 ± 2.24 days; hematospermia 14.4 %; dysuria, 15.7 % and 3.12 ± 2.71 days; urinary tract pain, 49.5 % and 2.43 ± 2.08 days; perineal pain, 35.5 % and 3.53 ± 2.59 days; fever ≥37 °C, 1.7 % and 1.79 ± 1.72 days; and headache, 22.1 % and 3.40 ± 2.10 days. Seventeen patients (1.1 %) required indwelling urethral catheterization for grade 2 urinary retention. Pre-biopsy International Prostate Symptom Score (p = 0.014) was an independent related factor for hematuria. Prostate volume (p = 0.001) was an independent related factor for grade 2 urinary retention. CONCLUSIONS: TRUS-guided TP prostate biopsy under lumbar spinal anesthesia can be performed safely with only minor adverse events.
BACKGROUND: Although transperineal (TP) prostate biopsy is growing in popularity, its safety has not been evaluated based on extensive studies. We prospectively assessed the adverse events associated with transrectal ultrasound (TRUS)-guided TP 16-core prostate biopsy at a single institution. PATIENTS AND METHODS: We enrolled 2,086 males who underwent first-time TRUS-guided TP prostate biopsy under lumbar spinal anesthesia at Chiba Cancer Center between 2009 and 2013. Eight adverse events were assessed prospectively using a purpose-designed questionnaire. The prevalence and duration of all adverse events were evaluated. We performed subgroup analyses for hematuria and urinary retention in relation to clinical factors. RESULTS: Questionnaires were collected from 1,663 cases (79.7 %). The cancer detection rate was 53.5 % in all patients. The prevalence and duration of complications were as follows: hematuria, 73.4 % and 4.51 ± 2.88 days; perineal bleeding, 7.1 % and 2.20 ± 2.24 days; hematospermia 14.4 %; dysuria, 15.7 % and 3.12 ± 2.71 days; urinary tract pain, 49.5 % and 2.43 ± 2.08 days; perineal pain, 35.5 % and 3.53 ± 2.59 days; fever ≥37 °C, 1.7 % and 1.79 ± 1.72 days; and headache, 22.1 % and 3.40 ± 2.10 days. Seventeen patients (1.1 %) required indwelling urethral catheterization for grade 2 urinary retention. Pre-biopsy International Prostate Symptom Score (p = 0.014) was an independent related factor for hematuria. Prostate volume (p = 0.001) was an independent related factor for grade 2 urinary retention. CONCLUSIONS: TRUS-guided TP prostate biopsy under lumbar spinal anesthesia can be performed safely with only minor adverse events.
Authors: N Masumori; T Tsukamoto; Y Kumamoto; L A Panser; T Rhodes; C J Girman; M M Lieber; S J Jacobsen Journal: Urology Date: 1999-08 Impact factor: 2.649
Authors: Tobias Klein; Rein Jueri Palisaar; Alexander Holz; Marko Brock; Joachim Noldus; Andreas Hinkel Journal: J Urol Date: 2010-08-19 Impact factor: 7.450
Authors: A Takenaka; R Hara; T Ishimura; T Fujii; Y Jo; A Nagai; M Fujisawa Journal: Prostate Cancer Prostatic Dis Date: 2007-05-29 Impact factor: 5.554
Authors: Jeremy P Grummet; Mahesha Weerakoon; Sean Huang; Nathan Lawrentschuk; Mark Frydenberg; Daniel A Moon; Mary O'Reilly; Declan Murphy Journal: BJU Int Date: 2014-02-19 Impact factor: 5.588
Authors: Lona Vyas; Peter Acher; Janette Kinsella; Ben Challacombe; Richard T M Chang; Paul Sturch; Declan Cahill; Ashish Chandra; Richard Popert Journal: BJU Int Date: 2014-04-03 Impact factor: 5.588
Authors: Spyridon P Basourakos; Mark N Alshak; Patrick J Lewicki; Emily Cheng; Michael Tzeng; Antonio P DeRosa; Mathew J Allaway; Ashley E Ross; Edward M Schaeffer; Hiten D Patel; Jim C Hu; Michael A Gorin Journal: Eur Urol Open Sci Date: 2022-01-29